Conduct of phase I trials in children with cancer

Riccardo Riccardi, Malcolm Smith, Mark Bernstein, W. Archie Bleyer, Joseph D. Borsi, Peter Ho, Ian J. Lewis, Andrew Pearson, Francois Pein, Charles Pratt, Gregory Reaman, Nita Seibel, Robert Trueworthy, Richard Ungerleider, Gilles Vassal, Teresa Vietti

Risultato della ricerca: Contributo in rivistaArticolo in rivista

71 Citazioni (Scopus)

Abstract

PURPOSE AND METHODS: Future progress in the care of children with cancer requires appropriate evaluations of promising new agents for pediatric indications, beginning with well-conducted phase I trials. This report summarizes current guidelines for the conduct of pediatric phase I trials and represents a consensus between American and European investigators. The primary objective of pediatric phase I trials is to define safe and appropriate doses and schedules of new agents that can subsequently be used in phase II trials to test for activity against specific childhood malignancies. Prioritization of agents for evaluation in children is critical, since many more investigational agents are evaluated in adult patients than can be systematically evaluated in children. Considerations used in prioritizing agents include activity in xenograft models, novel mechanism of action, favorable drug-resistance profile, and activity observed in adult trials of the agent. RESULTS AND CONCLUSION: Distinctive characteristics of pediatric phase I trials, in comparison to adult phase I trials, include the necessity for multiinstitutional participation and their higher starting dose (typically 80% of the adult maximum-tolerated dose [MTD]), both of which reflect the relative unavailability of appropriate patients. The application of uniform eligibility criteria and standard definitions for MTD and dose-limiting toxicity (DLT) help to assure that pediatric phase I trials are safely conducted and reliably identify appropriate doses and schedules of agents for phase II evaluation. Where possible, pediatric phase I trials also define the pharmacokinetic behavior of new agents in children.
Lingua originaleEnglish
pagine (da-a)966-978
Numero di pagine13
RivistaJournal of Clinical Oncology
Stato di pubblicazionePubblicato - 1998

Keywords

  • children
  • phase I trial

Fingerprint Entra nei temi di ricerca di 'Conduct of phase I trials in children with cancer'. Insieme formano una fingerprint unica.

Cita questo